RhumbLine Advisers
STOK icon

RhumbLine Advisers’s Stoke Therapeutics STOK Stock Holding History

RhumbLine Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.95M Sell
75,030
-901
-1% -$27.2K ﹤0.01% 1915
2026
Q2 		$2.48M Buy
75,931
+8,616
+13% +$277K ﹤0.01% 1833
2026
Q1 		$2.19M Buy
67,315
+4,901
+8% +$161K ﹤0.01% 1803
2025
Q4 		$1.98M Sell
62,414
-5,890
-9% -$177K ﹤0.01% 1883
2025
Q3 		$1.61M Buy
68,304
+1,885
+3% +$32.3K ﹤0.01% 2020
2025
Q2 		$754K Buy
66,419
+16,820
+34% +$160K ﹤0.01% 2395
2025
Q1 		$330K Buy
49,599
+225
+0.5% +$2.1K ﹤0.01% 2830
2024
Q4 		$545K Buy
49,374
+2,787
+6% +$34.2K ﹤0.01% 2629
2024
Q3 		$573K Sell
46,587
-1,273
-3% -$18K ﹤0.01% 2614
2024
Q2 		$647K Buy
47,860
+5,990
+14% +$80.9K ﹤0.01% 2483
2024
Q1 		$565K Buy
41,870
+899
+2% +$5.45K ﹤0.01% 2590
2023
Q4 		$215K Sell
40,971
-38
-0.1% -$162 ﹤0.01% 3156
2023
Q3 		$162K Sell
41,009
-1,166
-3% -$7.67K ﹤0.01% 3267
2023
Q2 		$448K Buy
42,175
+7,578
+22% +$80.6K ﹤0.01% 2756
2023
Q1 		$288K Buy
34,597
+406
+1% +$3.66K ﹤0.01% 2627
2022
Q4 		$316K Buy
34,191
+475
+1% +$4.94K ﹤0.01% 2660
2022
Q3 		$433K Buy
33,716
+1,865
+6% +$29.7K ﹤0.01% 2561
2022
Q2 		$421K Buy
31,851
+12,506
+65% +$190K ﹤0.01% 2585
2022
Q1 		$407K Buy
19,345
+1,362
+8% +$27.3K ﹤0.01% 2512
2021
Q4 		$431K Sell
17,983
-336
-2% -$8.02K ﹤0.01% 2570
2021
Q3 		$466K Buy
18,319
+849
+5% +$23.7K ﹤0.01% 2578
2021
Q2 		$588K Buy
17,470
+1,963
+13% +$69.4K ﹤0.01% 2495
2021
Q1 		$602K Sell
15,507
-165
-1% -$9.39K ﹤0.01% 2404
2020
Q4 		$971K Buy
15,672
+910
+6% +$41.7K ﹤0.01% 2141
2020
Q3 		$494K Sell
14,762
-2,115
-13% -$60.4K ﹤0.01% 2295
2020
Q2 		$402K Sell
16,877
-3,341
-17% -$79.3K ﹤0.01% 2441
2020
Q1 		$463K Buy
20,218
+12,279
+155% +$303K ﹤0.01% 2195
2019
Q4 		$225K Buy
+7,939
New +$200K ﹤0.01% 2711

Other funds holding STOK

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

RhumbLine Advisers's STOK Position: Q3 2026 in Review

RhumbLine Advisers reduced its Stoke Therapeutics (STOK) stake by 1.2% in Q3 2026, selling an estimated $27.2K and leaving 75,030 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1915.

RhumbLine Advisers first reported a position in STOK in Q4 2019 and has held it in 28 quarters since. The position peaked at $2.48M in Q2 2026. 120 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • RhumbLine Advisers held 75,030 shares of Stoke Therapeutics worth $1.95M as of Q3 2026.
  • RhumbLine Advisers sold 901 Stoke Therapeutics shares in Q3 2026, an estimated $27.2K.
  • Stoke Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1915 holding.
  • RhumbLine Advisers first reported a position in Stoke Therapeutics in Q4 2019 and has held it in 28 quarters since.
  • RhumbLine Advisers's Stoke Therapeutics position peaked at $2.48M in Q2 2026.
  • 120 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.